Sarepta Therapeutics, Inc. — Federal Contractor Profile
SAREPTA THERAPEUTICS, INC. Secures $2.88 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $2,878,511,254 ($2.9B)
Total Awards: 36
Company Profile
SAREPTA THERAPEUTICS, INC. is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for rare and ultra-rare diseases. The company's core capabilities include the discovery, development, and commercialization of novel therapeutics, particularly in the areas of neuromuscular diseases, lysosomal storage disorders, and other rare genetic diseases. SAREPTA has a significant presence in government contracting, with a total contract value of $2.88 billion over 36 contracts, averaging $7,99,58,646 per contract. However, the company has not won any new contracts recently, indicating a potential shift in its business strategy or challenges in securing new government work. The lack of specific agency clients and recent contracts suggests a diversified but potentially less active government business portfolio.
Specializations
- Neuromuscular diseases
- Lysosomal storage disorders
- Rare genetic diseases
- Gene therapy
- RNA-based therapies
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts were sole-source)
Agency Concentration: N/A (no specific agency clients)
Growth Trajectory: Stable (no recent contracts)
Sole Source Rate: 100%
Recompete Rate: 0% (no recompete/renewal contracts)
Competitive Position
SAREPTA THERAPEUTICS, INC. is a niche player in the biopharmaceutical sector, focusing on rare and ultra-rare diseases. The company holds a strong position in developing innovative therapies, particularly in gene and RNA-based treatments. However, its sole-source contracts and lack of recent activity suggest potential challenges in maintaining its market position and securing new government work.
Value to Taxpayers
SAREPTA THERAPEUTICS, INC. provides value through its focus on rare and ultra-rare diseases, which often have limited treatment options. The company's innovative therapies can offer significant benefits to patients, but the high contract values and sole-source nature of its contracts raise concerns about cost-effectiveness and competition. The lack of recent contracts and diversified agency clients may indicate potential risks to taxpayer value.
Agency Relationships
SAREPTA THERAPEUTICS, INC. has not specified any particular agency clients, indicating a potentially diversified but less active government business portfolio. The lack of recent contracts and specific agency relationships may pose dependency risks, as the company may be less reliant on any single agency, but also less active in securing new government work.
Red Flags
- Sole-source contracts: All 36 contracts were awarded through sole-source processes, raising concerns about competition and cost-effectiveness.
- No recent contracts: The absence of recent contracts suggests potential challenges in securing new government work, which could impact the company's financial stability.
- Lack of agency concentration: The company has not specified any particular agency clients, indicating a potentially less active government business portfolio.
Green Flags
- Innovative therapies: SAREPTA THERAPEUTICS, INC. focuses on developing novel treatments for rare and ultra-rare diseases, which can offer significant benefits to patients.
- Strong R&D capabilities: The company's core capabilities in gene and RNA-based therapies indicate a strong research and development focus, which can drive innovation and improve patient outcomes.
- Diversified portfolio: While the company has not specified any particular agency clients, its diversified portfolio suggests a broad range of potential government partners.
Key Contracts
SAREPTA THERAPEUTICS, INC. has secured a total of $2.88 billion in government contracts, with an average contract size of $79,958,646. These contracts primarily involve the development and commercialization of novel therapeutics for rare and ultra-rare diseases. The company's focus on gene and RNA-based therapies, particularly in neuromuscular diseases and lysosomal storage disorders, highlights its core capabilities and strategic direction. However, the lack of recent contracts and diversified agency clients may indicate potential challenges in maintaining its market position and securing new government work. The company's track record of successful projects, such as the development of Zolgensma for spinal muscular atrophy, demonstrates its ability to deliver innovative therapies, but the sole-source nature of its contracts raises concerns about competition and cost-effectiveness.
Frequently Asked Questions
What does SAREPTA THERAPEUTICS, INC. do for the federal government?
SAREPTA THERAPEUTICS, INC. specializes in the development and commercialization of innovative therapies for rare and ultra-rare diseases. The company's core capabilities include the discovery, development, and commercialization of novel therapeutics, particularly in the areas of neuromuscular diseases, lysosomal storage disorders, and other rare genetic diseases. Its focus on gene and RNA-based therapies, particularly in neuromuscular diseases and lysosomal storage disorders, highlights its core capabilities and strategic direction.
How much taxpayer money does SAREPTA THERAPEUTICS, INC. receive?
SAREPTA THERAPEUTICS, INC. has secured a total of $2.88 billion in government contracts, with an average contract size of $79,958,646. These contracts primarily involve the development and commercialization of novel therapeutics for rare and ultra-rare diseases, highlighting the significant investment in the company's research and development efforts.
Is SAREPTA THERAPEUTICS, INC. good value for taxpayer money?
SAREPTA THERAPEUTICS, INC. provides value through its focus on rare and ultra-rare diseases, which often have limited treatment options. The company's innovative therapies can offer significant benefits to patients, but the high contract values and sole-source nature of its contracts raise concerns about cost-effectiveness and competition. The lack of recent contracts and diversified agency clients may indicate potential risks to taxpayer value.
How does SAREPTA THERAPEUTICS, INC. win its contracts?
SAREPTA THERAPEUTICS, INC. has won all 36 of its government contracts through sole-source processes, indicating a focus on its innovative therapies and the limited competition in the rare disease market. The company's strong R&D capabilities and focus on gene and RNA-based therapies have likely contributed to its ability to secure these contracts.
What agencies use SAREPTA THERAPEUTICS, INC. most?
SAREPTA THERAPEUTICS, INC. has not specified any particular agency clients, indicating a potentially diversified but less active government business portfolio. The lack of recent contracts and specific agency relationships may pose dependency risks, as the company may be less reliant on any single agency, but also less active in securing new government work.
What are the risks of relying on SAREPTA THERAPEUTICS, INC.?
The risks of relying on SAREPTA THERAPEUTICS, INC. include the sole-source nature of its contracts, which raises concerns about competition and cost-effectiveness. The lack of recent contracts and diversified agency clients may indicate potential challenges in maintaining its market position and securing new government work. Additionally, the company's focus on rare and ultra-rare diseases may limit its potential for broader government engagement.
How does SAREPTA THERAPEUTICS, INC. compare to similar contractors?
SAREPTA THERAPEUTICS, INC. is a niche player in the biopharmaceutical sector, focusing on rare and ultra-rare diseases. The company holds a strong position in developing innovative therapies, particularly in gene and RNA-based treatments. However, its sole-source contracts and lack of recent activity suggest potential challenges in maintaining its market position and securing new government work. Compared to industry peers, SAREPTA THERAPEUTICS, INC. may face competition from larger, more diversified biopharmaceutical companies with broader portfolios and more active government business strategies.
Recent Federal Contracts
Sarepta Therapeutics, Inc. has 2 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| DoD's $106M advanced development contract for hemorrhagic fever treatments sh... | Department of Defense | $106.4M | N/A |
| DoD's $38.4M Antiviral Contract with Sarepta Therapeutics Faces Scrutiny for ... | Department of Defense | $38.4M | N/A |